细胞治疗市场规模、份额、成长分析、按治疗类型、按细胞类型、按治疗领域、按最终用户、按地区 - 行业预测，2024-2031

2022年细胞治疗市场规模为39亿美元，预计将从2023年的67亿美元成长到2031年的1,909.1亿美元，预测期间（2024-2031年）复合年增长率为52%。

探索细胞疗法的临床试验的激增正在推动细胞疗法领域的显着增长，并推动全球对研究和临床应用的投资增加。这种快速成长得到了政府机构和商业组织持续资助的支持，促进了临床试验各阶段的进展。同时，再生医学的进步有望彻底改变慢性病的治疗效果，美国和加拿大的先驱企业正在积极寻求利用新兴的细胞疗法市场的潜力。这些研究进展凸显了更有效治疗方法的有希望的途径，并强调了这一发展领域中研究创新和商业机会之间的动态相互作用。

目录

介绍

• 这项研究的目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 二手资料来源和主要资料来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 成功的关键因素
• 竞争程度
• Start-Ups分析
• 监管分析
• 技术分析
• 主要投资机会
• 市场吸引力指数
• 市场生态系统
• 案例研究

细胞治疗市场：按细胞类型

• 市场概况
• 干细胞
• 非干细胞

细胞治疗市场：依治疗类型

• 市场概况
• 同种异体疗法
  • 干细胞疗法
    • 造血干细胞治疗
    • 间质干细胞治疗
    • 其他的
  • 非干细胞疗法
    • 基于角质形成细胞和纤维母细胞的治疗方法
    • 其他的
• 自我治疗
  • 干细胞疗法
    • BM
    • 血
    • 脐带干细胞
    • 脂肪来源的细胞
    • 其他的
  • 非干细胞疗法
    • T细胞疗法
    • CAR T细胞疗法，
    • 基于 T 细胞受体 (TCR)
    • 其他的
  • 其他的

细胞治疗市场：依技术分类

• 市场概况
• 细胞处理
• 细胞储存、分配和处理
• 过程监控和品管

细胞治疗市场：依治疗领域

• 肿瘤学
• 心血管疾病（CVD）
• 肌肉骨骼疾病
• 皮肤科
• 其他的

细胞治疗市场：依最终用户分类

• 市场概况
• 医院/诊所
• 学术研究所
• 其他的

细胞治疗市场：按地区分類的规模

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 义大利
  • 英国
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• Thermo Fisher Scientific, Inc.（US）
• Merck KGaA（Germany）
• Danaher Corporation（US）
• Becton, Dickinson, and Company（US）
• Lonza Group（Switzerland）
• Sartorius AG（Germany）
• Nkarta, Inc.（US）
• Aurion Biotech（US）
• S. BIOMEDICS（Europe）
• MEDIPOST（South Korea）
• Anterogen Co., Ltd.（South Korea）
• JW Therapeutics（China）
• JCR Pharmaceuticals Co., Ltd.（Japan）
• Johnson & Johnson Services, Inc（US）
• Bristol-Myers Squibb Company（US）
• Gilead Sciences, Inc.（US）
• Novartis AG（Switzerland）
• Intellia Therapeutics（US）
• Iovance Therapeutics（US）
• CRISPR Therapeutics（Switzerland）

Cell Therapy Market size was valued at USD 3.9 Billion in 2022 and is poised to grow from USD 6.7 Billion in 2023 to USD 190.91 Billion by 2031, growing at a CAGR of 52 % during the forecast period (2024-2031).

The proliferation of clinical trials exploring cell-based therapies is fueling substantial growth within the cell therapy sector, prompting increased global investments in research and clinical applications. This surge is supported by continuous funding from governmental and commercial entities, facilitating advancements across various stages of clinical trials. Concurrently, progress in regenerative medicine is poised to revolutionize treatment efficacy for chronic diseases, with pioneering companies in the U.S. and Canada actively seeking to capitalize on the burgeoning market potential of cell therapy. These developments underscore a promising trajectory towards more effective therapeutic options and highlight the dynamic interplay between research innovation and commercial opportunity in this evolving field.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cell Therapy Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cell Therapy Market Segmental Analysis

The Cell Therapy Market is segmented by cell type, therapy type, therapeutic area, end-user and region. Based on Cell Type, the market is segmented into Stem Cells (Bone Marrow, Blood, Umbilical Cord-Derived, Adipose-Derived Stem Cell, and Others (placenta, and nonspecific cells)), and Non-stem Cell. Based on Therapy Type, the market is segmented into Allogeneic Therapies (Stem Cell Therapies (Hematopoietic Stem Cell Therapies, Mesenchymal Stem Cell Therapies) Non-Stem Cell Therapies (Keratinocytes & Fibroblast-based Therapies, Others), and Autologous Therapies (Stem Cell Therapies (BM, Blood, & Umbilical Cord-derived Stem Cells, Adipose Derived Cells, Others) Non-Stem Cell Therapies (T-Cell Therapies, CAR T Cell Therapy, T Cell Receptor (TCR)-based, Others) and Others). Based on the Therapeutic Area, the market is segmented into Oncology, Cardiovascular Disease (CVD), Musculoskeletal Disorders, Dermatology, and Others. Based on End Users, the market is segmented into Hospitals & Clinics, Academic & Research Institutes, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Cell Therapy Market

The need for innovative treatments targeting diseases such as cancer and cardiovascular disorders has spurred increased investment and research activity in cell-based approaches. This surge reflects a broader commitment to discovering and developing superior pharmaceuticals that can effectively combat these complex illnesses. The heightened demand for novel medicines has catalyzed extensive research initiatives and substantial financial backing specifically directed towards advancing cell-based research methodologies. These efforts aim to harness the potential of cellular mechanisms to create groundbreaking therapies, promising new avenues for treating and potentially curing some of the most challenging health conditions faced by humanity today.

Restraints in the Cell Therapy Market

In the past decade, despite significant technological advancements and continuous product development, the industry has faced persistent challenges due to a shortage of skilled personnel capable of operating complex devices like flow cytometers and multi-mode readers. This scarcity has impeded the sector's ability to fully leverage the latest technological innovations and achieve optimal operational efficiency. As these advanced instruments become more prevalent in research and industrial settings, the demand for proficient technicians and operators who can effectively utilize and maintain them continues to grow. Addressing this skills gap is crucial for organizations striving to maximize their technological investments and stay competitive in their respective fields.

Market Trends of the Cell Therapy Market

The cell therapy market has seen significant growth due to the increasing prevalence of chronic diseases, which are characterized as lasting a year or more and necessitating medical intervention that impacts daily life, according to the CDC. These conditions encompass heart disease, cancer, diabetes, and Parkinson's disease among others. Stem cell therapy offers potential benefits to patients suffering from various ailments such as spinal cord injuries, type 1 diabetes, Parkinson's disease, heart disease, cancer, and osteoarthritis.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Startup Analysis
• Regulatory Analysis
• Technology Analysis
• Top Investment Pockets
• Market Attractiveness Index
• Market Ecosystem
• Case Study

Cell Therapy Market by Cell Type

• Market Overview
• Stem Cell
• Non-stem Cell

Cell Therapy Market by Therapy Type

• Market Overview
• Allogeneic Therapies
  • Stem Cell Therapies
    • Hematopoietic Stem Cell Therapies
    • Mesenchymal Stem Cell Therapies
    • Others
  • Non-Stem Cell Therapies
    • Keratinocytes & Fibroblast-based Therapies,
    • Others
• Autologous Therapies
  • Stem Cell Therapies
    • BM
    • Blood
    • Umbilical Cord-derived Stem Cells
    • Adipose Derived Cells,
    • Others
  • Non-Stem Cell Therapies
    • T-Cell Therapies
    • CAR T Cell Therapy,
    • T Cell Receptor (TCR)-based
    • Others
  • Others

Cell Therapy Market by Technology

• Market Overview
• Cell Processing
• Cell Preservation, Distribution, And Handling
• Process Monitoring & Quality Control

Cell Therapy Market by Therapeutic Area

• Oncology
• Cardiovascular Disease (CVD)
• Musculoskeletal Disorders
• Dermatology
• Others

Cell Therapy Market by End User

• Market Overview
• Hospitals & Clinics
• Academic & Research Institutes
• Others

Cell Therapy Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • Italy
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Thermo Fisher Scientific, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson, and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sartorius AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nkarta, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurion Biotech (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• S. BIOMEDICS (Europe)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MEDIPOST (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anterogen Co., Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• JW Therapeutics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• JCR Pharmaceuticals Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intellia Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iovance Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CRISPR Therapeutics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments